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Endocrine, Cardiovascular, and Behavioral 
Responses to Clonidine in Patients with 
Panic Disorder 
James L. Abelson, Debra Glitz, Oliver G. Cameron, 
Myung A. Lee, Michael Bronzo, and George C. Curtis 
We examined adrenergic regulation in patients with panic disorder by challenging i0 
patients and 14 age-matched and sex-matched controls with intravenous infusions of 
clonidine hydrochloride (2 Izg/kg), an alpha2-adrenoreceptor agomst. Growth hormone, 
3-methoxy-4-hydroxyphenyiglycol (MHPG), blood pressure, heart rate, and behavioral 
(an:dety, sedation) responses were monitored. The data replicated the previously reported 
finding of blunted growth hormone (GH) responses to clonidine in patients with panic 
disorder. Reported abnormalities in MHPG, cardiovascular, and behavioral responses 
of panic patients to clonidine infusion were not replicated. The robustly blunted GH 
response to clonidine in panic patients supports the adrenergic dysregulation hypothesis 
of panic disorder, but alternative interpretations of this finding are available and further 
study is needed. 
Introduction 
Blunted growth hormone (GH) responses to clonidine infusion (Charney and Heninger 
1986; Nutt 1989; Uhde ct ai 1986) provide the most compelling evidence to date of an 
adrenergic abnormality in patients with panic disorder. However, one atlempt to replicate 
this finding has failed (Schittecatte et al 1988). Clonidine has also been reported to produce 
enhanced decreases in blood pressure and 3-methoxy-4-hydroxyphenylglycol (MHPG) 
and reduced sedation in panic patients compared to controls (Chamey and Heninger 1986; 
Nutt 1989); but these findings have not been uniformally replicated (Uhde et al 1989). 
The effect of clonidine on anxiety has also differed a~ross studies (Charney and Heninger 
1986; Uhde et al 1989). In an attempt to replicate the blunted GH reponses to clonidine 
in panic disorder, and to clarify the status of cardiovascular, MHPG, and sedation/anxiety 
responses, we conducted clonidine infusions in additional groups of panic patients and 
normal control subjects. 
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Methods 
Fourteen control subjects (mean age = 33.4 _+ 10.0 years, 7 men and 7 women) and 
10 panic patients (mean age = 35.6 -4- 5.5 years, 5 men) were studied. Patients met 
DSM-III criteria for panic disorder, had experienced at least three panic attacks in the 3 
weeks prior to study, were not currently depressed or abusing substances, and had no 
history of depression prior to onset of their panic disorder. No control subject had a 
history of any DSM-III Axis 1 disorder. Medical history, physical examination, and 
screening laboratory studies ensured that subjects were healthy and drug free for at least 
2 weeks before testing. Females were studied within the first 10 days of the menstrual 
cycle, were not menopausal, and were not taking oral contraceptives. Subjects with regular 
alcohol consumption equivalent to, or greater than, an average of four cans of beer per 
week were excluded. All subjects gave written informed consent. 
Procedures, assays, and analyses are described in detail elsewhere (Abelson et al 
1991). Briefly, subjects were studied on two mornings within an 8-day period following 
a night in a clinical research center. They were given single-blind infusions of placebo 
(10 ml of normal saline) on day I and clonidine hydrochloride (2 ~g/kg in 10 ml normal 
saline over 5 min) on day 2 (mean dose infused = 124 I~g). Blood samples were taken 
for GH and MHPG assay 15 min and immediately be|ore infusion, and at 15, 30, 45, 
60, 90, 120, and 180 min thereafter. Systolic (SBP) and diastolic (DBP) blood pressure, 
heart rate (HR), and symptom ratings (visual analog scales and Spielberger State Anxiety 
Scale) were obtained at each time point. Subjects were not permitted to sleep during the 
study. Subjective ratings of stress and anxiety for the 6 months prior to the study were 
obtained on day 1. Subjects completed the trait portion of the Spieiberger State-Trait 
Anxiety Inventory (STAI) (Spielberger et al 1969) and a Carroll Rating Scale for Depres- 
sion (Carroll et al 1981) on each study day. Sleep quality was rated on a 3-point scale 
(restful, fair, or poor). General level of exercise was rated on a 4-point scale (1 = no 
regular exercise, 4 = aerobic exercise ~> 3 times/week). Plasma GH was measured by 
double-antibody radioimmunoassay (Glick et al 1963) and plasma MHPG by high-per- 
formance liquid chromatography with coulometric detection (Hariharan et ai 1989). Hor- 
mone data was log-transformed to approximate normal distributions. Two subjects (I 
patient, I control) were excluded from GH analyses due to elevated baseline levels. One 
control subject was excluded from some GH and MHPG analyses due to a missed blood 
sample at the 45-min postinfusion time point. 
Results 
Clonidine strongly stimulated release of GH (repeated measures analysis of variance; 
main effect of drug: F[I,19] = 12.5, p < 0.005; drug-by-time interaction: F[8,152] = 
15.42, ,,, < 0.001), but did so less robustly in panic patients (diagnosis-by-drug, F[ 1,19] 
= 7.27, p < 0.05, and diagnosis-by-time, F[8,152] = 3.10, p < 0.005, interactions 
were both significant, though the three-way interaction was not, F[8,152] = 1.52, p = 
0.15). The blunted response of the panic patients was most evident at 30, 45, and 60 
min after infusion (see Figure 1). Six of nine (67%) panic patients were GH nonresponders 
(GH peak minus last baseline before infusion of less than 5 ng/ml), compared to 4 of 12 
control subjects (33%). 
Of the six panic patients who had blunted GH responses to clonidine, four were 
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Figure I. Growth homlone (GH) responses to placebo (upper graph) and clonidine (lower graph) 
in patients with panic disorder and normal subjects. Group means and SEMs arc plotted at each 
sampling point (15 and 0.5 rain before, and 15, 30, 45, 60, 90, 120, and 180 rain after infusion). 
The groups differed significantly (t-tests, p < 0.05) at the time points marked 'with asterisks. 
evaluated using structured interviews with reliable data about treatment histories and 
comorbid diagnoses. None of these four patients had any history of prior exposure to 
tricyclic antidepressant medication. None had any history of a major depressive episode. 
Only one of the four met criteria for generalized anxiety disorder or dysthymia (she met 
criteria for both). 
GH respouses to clonidine (mean of the GH level at 30, 45, and 60 min after infusion 
minus the GH level just prior to infusion) were not significantly correlated with Carroll 
depression scores, STAI trait anxiety, weight, exercise levels, or sleep quality. Higher 
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Figure 2. Plasma 3-methoxy-4-hydroxyphenolglycol (MHPG) responses to placebo (upper graph) 
and clonidine (lower graph) in patients with panic disorder and normal subjects. Group means and 
SEMs are plotted at each sampling point (15 and 0.5 min before, and 15, 30, 45, 60, 90, 120, 
and 180 rain after infusion). The groups differed significantly (t tests, p < 0.05) at the time points 
marked with asterisks. 
levels of stress and anxiety for the 6 months prior to study (self-rated on a 10-point scale; 
l = none, l0 = worst ever) were associated with more blunted GH responses (r = 
- 0 . 4 8 ,  p < 0.05 and r = - 0 . 5 4 ,  p < 0.05, respectively). 
Clonidine lowered MHPG levels (see Figure 2; main effect of time: F[8,176] = 3.23, 
p < 0.005; drug-by-time interaction: F[8,176] = 3.78, p < 0.001) but no interactions 
involving diagnosis were significant. Patients had higher MHPG levels than controls 
throughout the procedures, but the main effect of diagnosis was not significant 
(F[1,22] = 2.18, p = 0.15). The difference between groups in maximal MHPG change 
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Table 1. Maximum Decreases on Cardiovascular Measures After Clonidine Infusion a 
Patients with PD b Healthy controls 
Systolic blood pressure, mmHg 
Diastolic blood pressure, mmHg 
Heart rate, beats/min 
19.4 __ 4.2 17.9 +_ 4.1 
15.3 -4- 7.5 13.6 _+ 4.6 
6.1 _ 4.3 5.5 _+ 6.5 
'~Values are mean +- SD. 
bPD indicates panic disorder. 
after clonidine (lowest level after infusion minus mean baseline level) was not significant 
(t[22] = 1.61, p = 0.12; controls' mean maximal decline _+ SD = 0.5 _+ 0.3 p,g/L, 
patients' = 0.9 _+ 0.6 p,g/L). The small group difference became even smaller after 
declines following placebo were subtracted (t[22] - 0.90, p = 0.38; controls' mean = 
0.3 _ 0.04 p,g/L, patients' = 0.5 - 0.6 p,g/L). Because group differences were in the 
expected direction but not significant and our sample size was small, we pursued additional 
analyses. Examination of Figure 2 suggests that at 45 min after infusion the patient 
group's MHPG reached a nadir, whereas the control group's MHPG at this time point 
was near baseline. However, the placebo-corrected MHPG decline from baseline to 45 
min post-infusion did not differ between groups (t[22] - !.27, p = 0.22; controls' mean 
= 0.2 -+ 0.5 p,g/L, patients' = 0.5 + 0.6 p,g/L). We found no relationship between 
the GH response to clonidine and the maximal MHPG change (r = 0.22, p = 0.32). 
Clonidine reduce~i SBP and DBP in patients and controls (main effects of drug: 
F[1,22] = 117.66, p < 0.0001; F[1,22] = 4{).94, p < 0.001; main effects of time: 
F[8,176] = 27.07, p < 0.001; F[8,176] = 7.04, p < 0.001; drug-by-time interactions: 
F[8,176] = 19.78, p < 0.001; F[8,176] = 12.01, p < 0.001). None of the effects 
involving diagnosis were significant. Decline in HR following clonidine was reflected in 
a significant drug-by-time interaction (F[8,176] = 3.49, p < 0.001). There was a main 
effect of diagnosis i F[1,22] = 6.93, p < 0.05); but no interactions involving diagnosis 
were significant. Mean HR for patients over the entire monitoring period was 67.2 beats 
per rain, compared to 59.2 beats per min for controls. To maximize our chance of detecting 
group differences ia cardiovascular responses to clonidine we also compared groups on 
maximum responses, calculated by subtracting each subject's lowest value after infusion 
from their baseline. The groups did not differ on any of these variables (t[22] = 0.87, 
p = 0.40; t[22] = 0.65, p = 0.53; and t[22] = 0.29, p = 0.77, respectively; see Table 
1). 
Clonidine produced substantial sedation in patients and controls (main effects of drug: 
F[I,22] = 26.48, p < 0.001, and time: F[8,176] = 11.61, p < 0.001; drug-by-time 
interaction: F[8,176] = 14.16, p < 0.001). Patients had elevated ratings of drowsiness 
throughout the study (main effects of diagnosis: F[1,22] = 4.75, p < 0.05); but no 
interactions involving diagnosis were significant. The difference between groups in their 
peak drowsiness response to clonidine was not significant (t[22] = 0.88, p = 0.39; 
controls' mean increase in drowsiness rating from baseline to post-clonidine peak = 
4.3 _ 3. l, patients' = 5.8 _+ 1.8) and was opposite in direction to that predicted by 
prior research (increased rather than blunted sedative response). 
State anxiety was higher in patients throughout the study (main effect of diagnosis: 
F[l,19] = 39.83, p < 0.001), fell over the course of each day in both groups (main 
effect of time: F[8,152] = 7.21, p < 0.001), and fell to a greater extent in patients than 
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controls (diagnosis-by-time interaction: F[8,152] = 2.20, p < 0.05). However, the degree 
of anxiolysis did not differ between placebo and clonidine days (no significant effects 
involving drug) and was related to baseline levels (r = 0.55, p < 0.01). Similar results 
were obtained from analyses of analogue ratings of "worry." 
Discussion 
Four of five published studies have now demonstrated significantly smaller GH responses 
to clonidine in panic patients compared to controls (Charney and Heninger 1986; Nutt 
1989; Uhde et al 1986). Approximately 37 of the 56 panic patients studied to date (66%) 
have had blunted responses (less than a 5 ng/ml increase in GH after clonidine infusion), 
compared to approximately 18 of 57 control subjects (32%) (X 2 = 13.5, p < 0.001). 
The single failure to replicate (Schittecatte et al 1988) involved only seven subjects, and 
blunting was absent only in the female subjects, in whom birth control pills or menstrual- 
cycle phase can obscure blunting. It is unlikely that the GH bhmting seen in anxiety 
disorders is an epiphenomenon of tricyclic exposure as four of our six panic patients and 
all ~f our six generalized anxiety disorder patients (Abelson et al 1991) with blunted 
responses had no significant prior exposure to tricyclic antidepressants, 
Blunted GH response to clonidine is thought to reflect subsensitivity of post-synaptic 
alpha2-adrenoreceptors (Siever et al 1982), but its implications are complicated by a report 
of blunted GH responses to GH-releasing hormone (GHRH) in panic (Rapaport et al 
1989). Blunted GH responses to both clonidine and GHRH could result from chronic 
excessive adrenergic drive to the hypothalamus but abnormalities within the pituitary or 
in other neurotransmitter systems could also account for the findings. Studies that combine 
the use of GHRH and multiple adrenergic probes in the same subjects are needed. 
Only one placebo-controlled study of panic patients has demonstrated an enhanced 
decline in MHPG following clonidine infusion (Charney and Heninger 1986). A single 
replication did not include a control infusion and was complicated by elevated baseline 
MHPG in the patients (Nutt 1989). Our group difference were in the expected direction 
but were not significant. This failure to replicate could be caused by the small sample 
size. However, it appeared in our data that any potential differences between patients 
and controls in MHPG was present on both placebo and clonidine days and may not 
reflect differential responsivity to clonidine per se. 
Ours is the third of four studies to show no difference between patients and controls 
in SBP response to clonidine (Charney and Heninger 1986; Uhde et al 1989). The one 
report of an exaggerated decline in patients used a method of data analysis that should 
be more sensitive to briefer, less stable blood-pressure changes. However, we could n,~t 
detect group differences or even trends using either this or our preferred more conservative 
method. Enhanced declines in DBP have been demonstrated in two studies (Charney and 
Heninger 1986; Nutt 1989); but our data provide the second failure to replicate this finding 
(Uhde et al 1989). Studies are consistent in showing some "tonic" elevation of HR in 
panic patients but normal HR responses to clonidine. 
The two prior placebo-controlled studies examining acute anxiolyt:c activity of clon- 
idi~e in panic patients produced conflicting results (Charney and Heninger 1986; Uhde 
et al 1989). Our data and those of Charney and Heninger (1986) indicate that anxiety 
declines equally following placebo and clonidine infusions and patient-control differences 
are likely secondary to elevated baseline anxiety in patients. The group differences in 
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anxiolysis reported by Uhde et al (1989) could be due to substantially higher baseline 
anxiety in the patients. The greater decline in anxiety following clonidine rather than 
placebo, within their patient group, may also be due to baseline differences as the patients 
appear to have had higher baseline state anxiety scores on clonidine day than on placebo 
day. Given baseline effects on anxiety responses and the likely sensitivity of panic patients' 
baseline anxiety to experimental procedures, available data does not clearly demonstrate 
true pharmacological differences between panic patients and controls in their anxiolytic 
responses to clonidine infusion. Other experimental designs will be needed to conclusively 
show that clonidine possesses acute anxiolytic activity in panic patients. Our data, like 
those of Uhde et al (1989), did not replicate a blunted sedative response to clonidine in 
panic patients (Charney and Heninger 1986; Nutt 1989). The elevated mean drowsiness 
ratings in our patients, compared to controls, make it unlikely that failure to replicate 
was due to insufficient power. 
The blunted GH response to clonidine in patients with panic disorder appears highly 
reproducible. Other reported "abnormal" responses to clonidine in panic (i.e., enhanced 
declines in MHPG, blood pressure and anxiety, and reduced sedation) appear less repl- 
icable, because each has now failed to replicate at least twice. Small samples and dif- 
ferences in procedures could account for some of the inconsistencies. Variable baseline 
effects and other uncontrolled factors (e.g., weight and exercise levels) may also play a 
role. We cannot conclude from our small sample that panic patients do not have some 
abnormalities in MHPG, blood pressure, sedative, or anxiety responses to clonidine; but 
the inconsistencies in these variables across multiple studies make the reproducibility of 
the GH abnonnality all the more striking. GH blunting likely represents a true physio- 
logical abnorm:.dity in the regulation of the hypothalamic-pituitary-somatotrophic axis 
in panic patients. Whether it reflects subsensitivity of postsynaptic alpha2-adrenoreceptors 
remains to be proven. It does represent an unequivocal finding that requires further 
exploration. 
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